The spectrum and extent of islet cell histopathological findings in patients with multiple endocrine neoplasia, type I (MEN I) syndrome has never been clearly defined. Although some patients have discreet tumors causing clinically evident syndromes, others may have no symptoms until metastatic islet cell carcinoma is apparent. Whether diffuse islet cell disease occurs in all patients with grossly apparent tumors is not known. This study is an attempt to define both the functional and anatomical extent of islet cell disease and its relationship with the clinical course of patients with MEN I syndrome.
The resected specimens of pancreas from 14 patients with MEN I syndrome were evaluated for hyperplasia, nesidioblastosis, multiple tumors, and evidence of malignancy. In 12 cases, specimens consisted of distal pancreas and, in 2 cases, the entire pancreas was available. Multiple sections were taken from each specimen. Immunoperoxidase staining was done for gastrin, pancreatic polypeptide, glucagon, serotonin, VIP, somatostatin, and neuron-specific enolase in sections of 24 tumors from 10 patients. Five of the 10 patients with Zollinger-Ellison syndrome underwent total gastrectomy and 3 others underwent only pancreatic procedures to control their acid hypersecretion.
The following is concluded. All MEN I patients with pancreatic neoplasms have diffuse islet cell involvement consisting of nesidioblastosis, micro-and macronodular hyperplasia. Some tumors produce multiple hormones and these patients are at risk to develop new tumors, but complete excision of grossly apparent tumors may result in long-term control of the endocrinopathy present. This is particularly true for patients with insulinoma and hypoglycemia. Selected patients with gastrinoma may also be considered for excision of their islet cell tumor(s) without concomitant gastrectomy, especially if transhepatic venous sampling demonstrates a single site of excess gastrin production. However, if transhepatic venous sampling demonstrates diffuse sources of hypergastrinemia, a local pancreatic procedure will invariably be unsuccessful. Total pancreatectomy in MEN I patients with disease localized to the pancreas is the only curative surgical procedure but is rarely indicated.
The extent of islet cell histopathological findings in patients with multiple endocrine neoplasia, type I (MEN I) syndrome has never been clearly defined. Although some patients with clinically detectable tumors present with recognizable symptoms, others may have no symptoms until metastatic islet cell carcinoma is apparent. Some patients with clinical findings such as Zollinger-Ellison syndrome (ZES) have no demonstrable gross pancreatic findings [1] [2] [3] [4] [5] . Whether diffuse islet cell disease is present in all patients with grossly apparent tumors is not known. Furthermore, it is not known how frequently new tumors develop in patients with MEN I syndrome after local excision or partial pancreatectomy for primary islet cell tumors. The present study was done to better define the functional and anatomical extent of islet cell disease in MEN I patients and to correlate it with the postoperative clinical course. Based on this study we hope to develop a more rational therapeutic plan for the pancreatic component in patients with MEN I syndrome. 
Methods and Materials

Patients
The case records of 14 MEN I patients who underwent partial or total pancreatectomy for islet neoplasms were reviewed carefully for clinical symptoms as well as for laboratory and operative findings. In 12 patients who survived, postoperative symptoms, laboratory, and other diagnostic studies were also reviewed. In addition, each of the patients was re-examined, and serum was obtained for determination of gastrointestinal polypeptide hormone levels. Other studies, including abdominal computed tomography scans, were obtained when indicated. Follow-up in 12 living patients has been complete to date (Table 1) .
Pathological Methods
The resected specimens of pancreas from the 14 patients with proven MEN I syndromes were evaluated for gross and microscopic tumors, evidence of malignancy, islet cell hyperplasia, and nesidioblastosis. Lymph nodes removed at the time of operation, or at autopsy (in l case), were also evaluated. All but 2 specimens consisted of distal pancreas. Any islet cell tumors that had been enucleated from the pancreatic head, uncinate process, or duodenum were also evaluated in each case. The latter specimens were all obtained surgically at the time of exploration in patients with either Zollinger-Ellison syndrome or organic hyperinsulinism. In ! case, 2 incidental pancreatic tumors were resected during an operation for cholelithiasis. In another case, the entire pancreas was available for evaluation following total pancreatectomy for an adenocarcinoma arising in the head of the pancreas. The pancreas was removed at autopsy in 1 patient, after the patient had died from hypercalcemic crisis before any surgical intervention. In each case, multiple sections of tumors and nontumorous pancreas were stained with hematoxylin and eosin and reviewed using light microscopy.
Immunohistochernical Localization
In 10 cases, immunohistochemical staining for detection of polypeptide hormones, serotonin, and neuron-specific enolase (NSE) was done in 1 or more tumors. The method consisted of cutting 4-~ sections of formalin-fixed, paraffin-embedded tissues and immuno-peroxidase staining them using the avidin-biotin complex method (ABC) with an unlabeled primary antibody and biotinylated secondary antibody in a performed avidin:biotin horseradish peroxidase complex (Vector Labs, Burlingame, CA) [6] . In addition, the specificity of each antiserum was examined by specific absorption with appropriate antigens. The concentrations of antigens used to absorb the antisera ranged from 10 to 100 ng/ml in purified form.
Results
Patients
There were 10 female and 4 male MEN I patients in this study group (Table 1) . Only 2 patients (nos. 4 and 9) were members of the same kindred. The mean age of all patients at the time of diagnosis of pancreatic islet cell disease was 42.5 years. The mean age was 41.4 years (range 2%52) for females and 45.5 years (range 28-52) for males. Eight of 10 patients had ZES confirmed by demonstrating gastric hyperacidity (BAO-MAO ratio greater than 0.6), elevated basal serum gastrin levels, or a paradoxical rise in serum gastrin levels after stimulation with intravenous secretin. One patient (no. 2) died from hypercalcemic crisis and massive hemorrhage from a duodenal ulcer within an hour of hospitalization. Autopsy demonstrated massively enlarged parathyroid glands, a pituitary microadenoma, an islet cell adenoma, and a large duodenal ulcer [7] . One patient (no. 1) underwent total gastrectomy before serum gastrin assays were available but has since demonstrated elevated serum gastrin levels. Since 1979, a total of 7 patients (nos. [8] [9] [10] [11] [12] [13] [14] have had selective portal venous sampling for gastrin and other gastrointestinal polypeptide hormones prior to a planned pancreatic operation [8, 9] . Two patients presented with episodic hypoglycemia (nos. 3 and 6) and were found at operation to have insulinomas. Both had preoperative insulin/glucose ratios greater than 0.3. Neither has had recurrent symptoms or laboratory evidence of hypoglycemia since undergoing distal pancreatectomy. One patient (no. 9) who had undergone subtotal parathyroidectomy had no gastrointestinal symptoms during a 5-year period until he suddenly developed obstruction of the second portion of the duodenum. During this asymptomatic interval, his serum pancreatic polypeptide level was consistently elevated. Repeated serum gastrin levels were normal until he developed duodenal obstruction. This patient was found at operation to have an adenocarcinoma of the pancreatic head invading the duodenum [9] . In addition, he had multiple islet cell adenomas, extensive nesidioblastosis, and islet cell hyperplasia involving the entire pancreas. After an uncomplicated recovery following a total pancreatectomy, he developed metastases 6 months later and died shortly afterward. One patient (no. 11) without any symptoms related to the pancreas had 2 islet cell adenomas in the body of the pancreas at the time of a cholecystectomy. The adenomas, which measured 4 and 2.5 cm, respectively, were resected with the body and tail of the pancreas. This patient had undergone a subtotal parathyroidectomy for chief cell hyperplasia 5 years previously at age 23 years. Eleven patients had undergone previous parathyroidectomy before any manifestations of islet cell disease developed (mean interval 3.9 years). The remaining 3 patients were hypercalcemic at the time their pancreatic disease was discovered. The duration of antecedent hyperparathyroidism cannot be documented clearly but 2 of these patients had renal calculi for at least 3 years. Of these 3 patients, 2 had parathyroidectomy before their pancreatic operation. The remaining patient died from hypercalcemic crisis before any operation could be undertaken. Thus, each of the 13 patients undergoing a pancreatic operation had a previous parathyroidectomy. All had chief cell hyperplasia of all 4 parathyroid glands. In each case, all but the equivalent of 1 normal parathyroid gland (30-50 rag) was resected. All patients are currently normocalcemic.
Nine of the 14 patients had pituitary tumors documented by CT scanning, abnormal pituitary hormone levels, hypophysectomy, or autopsy. Two patients (nos. 5 and 10) underwent hypophysectomy before either parathyroid or islet cell disease was treated. Another patient (no. 14) was treated with bromocryptine for 2 years before symptoms of ZES developed.
Three patients had evidence of adrenocortical disease. Of these, 2 (nos. 2 and 7) had clinical manifestations of Cushing's syndrome. Of the 10 Z E S p a t i e n t s , 5 had total gastrectomies in a d d i t i o n to p a n c r e a t i c resections. Only 1 of the 5 M E N I p a t i e n t s o p e r a t e d on since 1979 has had a gastric r e s e c t i o n . All have u n d e r g o n e distal p a n a t e c t o m y with or w i t h o u t enucleation of tumor(s) in the h e a d o f the p a n c r e a s or d u o d e n u m . One patient had e x c i s i o n o f 3 small t u m o r s from the d u o d e n u m and p a n c r e a t i c h e a d and a c o n c o m i t a n t v a g o t o m y and p y l o r o p l a s t y . C u r r e n t l y , these patients are all doing well and none requires a n t a c i d s or cimetidine. H o w e v e r , their s e r u m gastrin levels are n o w either b o r d e r l i n e n o r m a l or slightly ele v a t e d . All n o w d e m o n s t r a t e a positive gastrin res p o n s e to i n t r a v e n o u s secretin stimulation. T h r e e patients (nos. 1 , 3 , and 7) w h o u n d e r w e n t total gast r e c t o m y c u r r e n t l y h a v e e l e v a t e d serum gastrin levels but no clinically d e t e c t a b l e m e t a s t a t i c disease. T h e y r e m a i n s y m p t o m free at 21 y e a r s , 8 years, and 5 y e a r s , r e s p e c t i v e l y , after o p e r a t i o n . O n e of these patients was e x p l o r e d 5 y e a r s following total gast r e c t o m y for an u n r e l a t e d r e a s o n and was found to have a firm p a n c r e a t i c h e a d but no p a l p a b l e t u m o r or e v i d e n c e of m e t a s t a t i c disease. S e r u m gastrin levels have r e m a i n e d near 1,000 pg/100 ml for 5 y e a r s in this patient. hyperplasia and microadenomas in all 14 patients ( Table 2 , Fig. 1 ). Nesidioblastosis (islet cells arising from exocrine ducts) was demonstrated in all but 1 patient (no. 4). Grossly visible tumors were present in 13 of 14 patients and were multiple in 7. Two patients had duodenal islet cell tumors in addition to pancreatic neoplasms (Fig. 2) . Most of the tumors were 2 cm or smaller in maximum diameter. The largest tumor was an 11-cm " a d e n o m a " involving the body and tail of the pancreas in a patient with ZES (Fig. 3) . In 4 patients, single, enlarged peripancreatic lymph nodes were found to contain microscopic metastases. One patient (no. 9) with metastatic adenocarcinoma in a peripancreatic lymph node and a primary adenocarcinoma of pancreatic duct origin, arising in the head of the pancreas, also had multiple islet cell tumors. No patient with islet cell tumors was proven to have hepatic metastases at operation or subsequent follow-up. tumors from 10 patients were studied. In all but I patient (no. 2), more than 1 tumor was found. In the most recent patient (no. 14), a metastatic lymph node was stained in addition to 3 tumors. In this patient with ZES, the metastatic lesion was positive for somatostatin only; this peptide was also demonstrated in 1 of the 3 pancreatic tumors. Of 8 patients with ZES, 6 were found to have gastrin in at least 1 of the tumors studied. The 1 patient with hypoglycemia was found to have insulin in 1 of 3 neoplasms, whereas the other tumors had both glucagon-and gastrin-positive cells. Eight of 10 patients had PP within their tumors and 18 of 24 neoplasms had PP-containing cells. Every tumor stained positively for neuron-specific enolase. Heterogeneity of endocrine cells within individual neoplasms was demonstrated in 17 (71%) of 24 tumors.
Pathological Findings
Discussion
Immunohistochemical Findings
The results of immunohistochemical localization studies for selected polypeptide hormones, serotonin, and NSE are shown in Table 3 . Twenty-four This study suggests that the pancreas is uniformly involved in patients with M E N I syndrome. Where complete pathological data have been reported, the pituitary, parathyroids, and pancreas have been involved [10] . However, the extent and nature of the pancreatic involvement, other than for gross tumors, have frequently been omitted. This study clarifies the extent of islet cell disease and relates 
-PP = pancreatic polypeptide; INS = insulin; Serot = serotonin; GLU = glucagon; SRIF = somatostatin; VIP = vasoactive inhibitory peptide; NSE = neuron-specific enolase.
hi, II, III are different tumors; IV is metastatic lymph node +f = focal stainins of tumor cells.
it to the functional aspects of the disease process.
In each of the cases studied, diffuse islet cell disease was found. With the exception of 1 patient, hyperplasia and nesidioblastosis were demonstrated in all specimens from patients in whom neoplasms had been excised at operation or at autopsy. In the patient without nesidioblastosis, multiple sections showed hyperplasia and microadenomatosis. All patients had microadenomas occurring throughout the non-tumor-containing areas of pancreas. Some tumors produced multiple hormones and were composed of heterogeneous islet ceils. Most patients had tumors that stained for one or more gut or pancreatic hormones. These findings are consistent with the observation that metachronous hormonal syndromes have been reported in MEN I patients with the ZES and hypoglycemic syndromes; synchronous syndromes (ZES and glucagonoma) occur less frequently [! 1, 12] . In our experience the two most common "silent" hormones found in islet cell neoplasms and microadenomas were pancreatic polypeptide (PP) and somatostatin. The presence of PP in many microadenomas corresponds in frequency to elevated serum levels of this hormone found in patients with MEN I syndrome [3] [4] [5] . We believe that if somatostatin samplings were routinely obtained in MEN I patients, levels of this hormone might also be elevated frequently. Although tumors producing either hormone alone are infrequent in the reported experience with MEN I patients, this may represent lack of recognition rather than lack of occurrence [8, 13] . In most cases these tumors may be histochemicaIly active but clinically silent. All of the islet ceils, including stem cells arising from exocrine ducts, stained intensely with neuron-specific enolase. This study supports the observation that this enzyme is a universally present marker in neuroendocrine cells [6] .
The incidence of proven malignancy in this group of patients was 29% and only 1 patient developed documented hepatic metastases. This low incidence of metastatic disease is surprising, particularly for the group of patients with ZES (20%), since it has been shown previously that 60% or more of such patients have malignant tumors as determined by metastases at the time of diagnosis [1, 4, [14] [15] [16] . Two of the ZES patients are noteworthy; the longest survivor at 21 years was found to have ! positive lymph node at the time she underwent distal pancreatectomy and total gastrectomy. A 43-year-old female patient with a short history of diarrhea due to gastric hypersecretion had an 11-cm tumor but no metastases or local invasion. Like the other ZES patients, she continues to have a positive secretin response (rise in serum gastrin of 200 pg/ml from basal levels). None of these patients has developed liver metastases.
The occurrence of adenocarcinoma arising in the MEN I pancreas is rare but may not be mere coincidence. Patient no. 9 had been followed for 5 years after a subtotal parathyroidectomy. Throughout that time, fasting serum levels of pancreatic polypeptide were markedly elevated. To rule out the possibility of a pancreatic tumor, he underwent selective pancreatic arteriography. The study was considered normal. At the time of total pancreatectomy 4 years later, the entire pancreas was grossly thickened and slightly nodular. The islet cell histopathological finding was the most extreme seen in any patient. The combination of nesidioblastosis, islet cell hyperplasia, and micro-as well as macroadenomatosis, had nearly replaced the normal acinar pancreas. The adenocarcinoma, arising in the head of the pancreas, was surrounded by a rim of islet cells that stained positively for gastrin. Serum gastrin levels were first elevated just prior to operation at which time selective portal venous sampling showed a slight but definitely positive gradient for gastrin in the head of the pancreas. This adenocarcinoma may be an example of a "reversed nesidioblastosis," a regression or de-differentiation from islet cell to adenocarcinoma. At least one other similar case has been reported [9] .
Since all of the patients diagnosed since 1975 were known to have MEN I syndrome because of family history, asymmetrical parathyroid hyperplasia, or pituitary adenomas, the islet cell disease may have been detected at an earlier stage than in many previous reports. This may have resulted in a lower than expected rate of malignancy. Several patients were screened annually for pancreatic endocrine disease. In 2 MEN I patients with hypergastrinemia and peptic ulcer disease, serum gastrin levels returned to normal after correction of the hypercalcemia. In patient no. 4, hypergastrinemia developed 3 years after a successful parathyroidectomy. The first manifestation of ulcer disease was an acute perforation of the duodenum. At operation, 2 small tumors were palpable within the body of the pancreas. The patient was treated with distal pancreatectomy and total gastrectomy. AIthough asymptomatic, she was thought to have hepatic metastases because of a suspicious liver scan and progressively rising serum gastrin levels to over 1,000 pg/ml during a 5-year period. Selective pancreatic venous sampling showed that the only positive gastrin gradient occurred in the region of the head of the pancreas. When explored during a hysterectomy in 1981, no tumor was palpable in the liver, lymph nodes, or the thickened pancreatic head.
It is not known whether MEN I patients with malignant gastrinomas or other islet cell tumors really have a better prognosis than those with sporadic islet cell malignancies. In one of the few studies to evaluate sporadic gastrinomas separately from those occurring in patients with the MEN I syndrome, it was found that only 1 (7%) of 14 patients with MEN I gastrinoma had died as a result of disease progression during a follow-up period of 5 years or longer [17] . Because these patients continued to manifest hypergastrinemia after pancreatic operations despite a stable clinical course, it was concluded that MEN I patients with ZES should not undergo abdominal operation. However, Friesen reported long-term results in 23 ZES patients and found that 8 tumor deaths had occurred, 4 in patients with MEN I syndrome [4] . Two MEN I patients with liver metastases survived for 9 and l l years, respectively, after total gastrectomy. Most authors fail to distinguish between sporadic and MEN I gastrinomas or only mention the incidence of each without any further details [1, 2, 14, 16, 18] . It is clear, however, that some MEN I patients with ZES do eventually die from their neoplasms. The presence or potential for malignancy cannot be ignored if these patients are to have optimal management of their disease.
Despite the apparent futility of eliminating hypergastrinemia in MEN I patients by anything less than a total pancreatectomy, it appears that most patients with hypoglycemia can be effectively treated if all primary macroscopic tumors and metastases are removed. In this series, 2 MEN I patients with organic hypoglycemia had excellent results following distal pancreatectomy. Follow-up in these patients ranged from 5 to 10 years. In the patient followed for 10 years, a single lymph node metastasis confirmed that the primary neoplasm was malignant. Both of these patients were operated on before selective venous insulin sampling was available. In each case, all palpable tumor was removed with the resected specimen. Recently, we have had the opportunity to study an MEN I patient who was referred because of persistent hypoglycemia following enucleation of an insulinoma in the tail of the pancreas [19] . By using selective venous sampling, a second tumor was localized to the body of the pancreas. This lesion was subsequently removed by distal pancreatectomy. It is of interest that immuno-peroxidase staining of tumors from 5 patients without hypoglycemic symptoms were positive for insulin. Four of these tumors were shown to produce other hormones as well. Whether or not resection of these tumors has prevented the development of hypoglycemia in some of these patients is unknown. Demonstration of insulin production by these tumors may not necessarily correlate with biological activity. In these patients, all of whom have diffuse islet cell dysplasias, tumors secreting other hormones may also be present or develop later in the course of the disease. Preoperative localization of the source of excess insulin secretion in the MEN I patient is, therefore, of great therapeutic importance [19] . In contrast to ZES patients, of whom 30-40% are classified as MEN I, only 3-4% of patients with "insulinomas" are afflicted with this disorder [7] .
The pathological findings of the MEN I pancreas have not been clearly defined except in isolated case reports. In the present study, islet cell neoplasms 1 cm or larger were identified in all but I patient with ZES. The majority of patients (9 of 14) had more than 1 tumor and all patients had diffuse hyperplasia and microadenomas throughout the non-tumorous pancreas. Nesidioblastosis was also present in nearly all sections reviewed. This histopathologic study suggests that MEN I patients have diffuse dysplasia of islet tissue from which adenomas and islet cell carcinoma may develop. The factors that promote the development and growth of these tumors are unknown. In this series, the mean age at the time of tumor diagnosis was 43 years. However, 3 of the most recent patients were diagnosed before the age of 30. Two of these patients had hypergastrinemia with minimal symptoms but were studied because of parathyroid hyperplasia or a positive family history. It is likely that in the past such patients may well have been followed for many years before their islet cell disease was recognized. We have not seen peptic ulcers or other manifestations of MEN I islet cell disease in any patient under the age of 25 years. When children have ZES, they usually have sporadic, single gastrinomas rather than MEN I syndrome [18] . MEN I patients appear to be at life-long risk for the development of pancreatic disease. This point was recently emphasized in a report of an MEN I octogenarian who presented with functional islet cell tumors [20] .
The present study supports the contention that MEN I patients may have tumors with the potential to secrete multiple hormones. Based on immunohistochemical studies, our review has shown that all patients have tumor(s) with the potential to secrete more than 1 hormone. The lack of PP in the tumors of 2 ZES patients does not necessarily imply that other adenomas or hyperplastic islet cells secreting this peptide were absent. However, it is noteworthy that in 1 of these :patients (no. 13), preoperative selective venous assays for PP were within the normal range. This contrasts with the high levels seen in most other MEN I patients undergoing similar studies. In our series, gastrin was identified in at least 1 tumor in 6 of the 8 patients with ZES and in 1 patient with hypoglycemia who had no evidence of ulcer disease or diarrhea. This finding is in accord with reports of others who studied gastrinomas by the immunoperoxidase method [21] [22] [23] [24] [25] . In a study by Solcia et al. [24] , gastrin was found by immuno-peroxidase techniques or by extraction in 25 of 36 pancreatic tumors from ZES patients. Creutzfeldt et al. [21] reported similar findings in 20 of 2! ZES tumors as did Woodtli and Hedinger [25] in 7 of 9 patients. Failure to identify gastrin is most likely explained by inappropriate fixation and processing of tumor tissue or sampling deficiencies when multiple tumors are present [23] . Another possibility is that rapid turnover can result in tumor cell depletion, reducing the amounts of stored gastrin to levels too small for immunocytochemical detection [24] . A further explanation is that gastrin might be secreted by newly formed islet cells arising from ductal epithelium. This explanation appears unlikely in view of endocrine cell studies in patients with pancreatic or duodenal gastrinomas by Solcia et al. [24] . They were unable to demonstrate gastrin-immunoreactive cells in the non-tumorous pancreas. Cells exhibiting nesidioblastosis and hyperplastic islet cells were positive for PP, glucagon, somatostatin, or insulin. Whether functioning microadenomas can produce enough gastrin to cause hypergastrinemia in patients with ZES cannot be proven from this or other studies. In this series, 1 patient with ZES had no grossly identifiable tumor on sectioning the entire pancreas. In view of the high incidence of negative pancreatic explorations in ZES patients, it seems reasonable to speculate that microadenomas may be the source of excessive gastrin production rather than a non-pancreatic source [2, ll] .
The pathological findings in this study suggest that patients with MEN I pancreatic disease may not be "cured" by any surgical procedure less than total pancreatectomy because of the diffuse nature of the islet cell dysplasia. On the other hand, clinical experience does not justify total pancreatectomy because of the initial operative mortality rate, the possibility of undetected hepatic metastases, long-term morbidity from insulin-dependent diabetes, and the reasonably good prognosis for the ma-jority of patients treated by less extensive procedures [17] . In the present series, 1 total pancreatectomy was done because of the rare synchronous occurrence of pancreatic ductal adenocarcinoma with MEN I pancreatic disease. Of 14 MEN I patients, this was the only case in which the serum gastrin level returned to normal after operation. In a recently reported series, a total pancreatectomy was done for the synchronous occurrence of hypoglycemia and ZES [11] . Both syndromes were apparently cured. In another series of patients in which a small subgroup of patients was treated by Whipple procedures, the operative mortality rate was 50% [1] . In contrast, patients in that same series, who had islet cell hyperplasia without neoplasms, did well after total gastrectomy without pancreatic resection. Eleven patients, followed for 1-15 years, were alive without evidence of metastatic disease. Another subset of patients in the series of Bonfils et al. [1] with a favorable prognosis included those with duodenal gastrinomas. In 13 patients, only 4 had lymphatic metastases. Resection of the primary tumor could be accomplished in all but 1 patient. Eleven patients followed for a period of 1-14 years did well except for one who died of tumor. In the present series, at least 2 patients had duodenal tumors in addition to pancreatic neoplasms. Whether duodenal neuroendocrine tumors are more common in MEN I patients than in sporadic cases of ZES is not currently known [26] [27] [28] . However, because duodenal neuorendocrine cell hyperplasia is common in patients with gastrinomas, this possibility merits further study. The duodenum should always be completely evaluated in MEN 1 patients [24] .
All MEN I patients should be studied for the commonly occurring gastrointestinal-pancreatic (GEP) hormones. Virtually any GEP hormone as well as calcitonin and ACTH may be found in MEN I tumors [29, 30] . Although it is unlikely that even when a localized source of gastrin secretion is found it will lead to permanent cure after pancreatic operations in MEN I patients with the ZES, palliation without total gastrectomy can be achieved [8, 17] . In 4 of the present patients, enucleation of duodenal and pancreatic tumors, combined with distal pancreatectomy, has alleviated all peptic ulcer symptoms without the need for gastrectomy or cimetidine during a l-4-year follow-up. Despite this fact, all 4 patients have elevated serum gastrin levels when stimulated with secretin. These patients may eventually require further medical or surgical therapy. In contrast, it is estimated that approximately 20% of patients with sporadic gastrinomas of either the pancreas or duodenum are amenable to local resection or enucleation with probable cure as determined by secretin testing after operation [1, 2, 4, I l, 17, 26, 28, 31-33] . Appropriate candidates for local resection may be identified by portal venous gastrin sampling [8, 34, 35] . With earlier diagnosis of Zollinger-Ellison syndrome using gastrin radioimmunoassays, the opportunity to cure sporadic patients surgically may be further increased [36, 37] .
Our current policy is to recommend selective pancreatic and hepatic venous sampling in any MEN I patient in whom an operative procedure is contemplated [8, 9, 34, 35] . If there is evidence of diffuse gastrin secretion from the pancreas, it is unlikely that a primary pancreatic procedure will afford long-term relief [8] . Further studies, including CT and selective arteriography, should be done to identify any gross neoplasms or metastases. If none is found, a decision can be made regarding medical therapy versus total gastrectomy. As an alternative, pancreatic exploration with enucleation of any palpable tumors in the duodenum or pancreatic head, and distal pancreatectomy to remove microadenomas or to reduce potential sources of neoplasms should be considered. Whether vagotomy is of any additional benefit in these circumstances is currently debatable [17, 38, 39] . Any decision to do a total gastrectomy must be individualized. These decisions should be based on the severity of preoperative peptic ulcer disease, the ease with which acid secretion can be controlled with cimetidine, the age of the patient, and the presence or absence of metastatic disease.
If venous localization studies or CT scanning demonstrates a solitary pancreatic neoplasm, exploration is indicated. If the tumor is located in the pancreatic head or duodenum and if there is no local invasion, enucleation may be performed. Because of the presence of diffuse islet cell dysplasias in patients with MEN I syndromes, we recommend concomitant distal pancreatectomy to remove other small, undetectable, functional or nonfunctional islet cell neoplasms. Reducing the bulk of the pancreas may reduce the potential for developing other malignant islet cell neoplasms. A total pancreatectomy is the only procedure that may be considered curative in the MEN I patient without metastases. However, the benefits of this operation are outweighed by the operative mortality rate and long-term morbidity of insulin-dependent diabetes.
Most MEN I patients who present primarily with hypoglycemia can be cured by a single pancreatic operation [5, 9, 13, 15, 19] . Because of the small size and multiplicity of tumors in this syndrome, preoperative selective portal venous insulin samples should be obtained in all patients regardless of whether selective arteriography has identified one or more tumors. These patients should also be treated with distal pancreatectomy in addition to excision of any tumors found in the proximal pancreas. This therapy will increase the likelihood of excising other discreet yet undetectable insulinomas and will decrease the possibility of leaving non-insulin-producing neoplasms which may result in additional morbidity. In these cases, intraoperative ultrasound may be of particular value in locating small, nonpalpable tumors in the remaining pancreas [40, 41] . All available evidence suggests that hypoglycemic MEN I patients have discreet tumors as the source of their hyperinsulinism rather than either hyperplastic beta cells or nesidioblastosis that may occur as sporadic endocrinopathies in adults [19, 35, 4245] . In the latter cases, a more extensive pancreatectomy (80-95%) may be required to control the patient's hyperinsulinism [29] .
Distal pancreatectomy with enucleation of other functional and silent tumors found in the head of the gland should be considered in managing islet cell disease in the MEN I syndrome. All of these tumors are potentially malignant, and their early detection and excision may prevent tumor-related deaths. Long-term follow-up of all MEN I patients should include periodic reassessment of gastrointestinal-pancreatic hormone levels and CT examination of the remaining pancreas.
R6sum6
L'histopathologie des cellules insulaires pancr6a-tiques des malades qui prdsentent un syndrome MEN I n'a jamais 6t6 parfaitement ddfinie. Si certains parmi eux sont porteurs de petites tumeurs qui se manifestent par des syndromes cliniques patents, d'autres n'accusent aucun sympt6me avant que des mdtastases n6oplasiques ne se manifestent. En particulier, on ne salt pas si les altdrations des cellules insulaires sont diffuses quand les malades pr6sentent des tumeurs 6videntes. Cette 6tude apour but de ddfinir/t la fois l'importance anatomique et l'importance fonctionnelle de la maladie insulaire par rapport ~t son expression clinique chez les sujets concern6s par ce syndrome.
Pour ce faire, des sp6cimens provenant de 14 malades atteints du syndrome MEN I ont 6td 6tudi6s eu 6gard ~ l'hyperplasie, ~t la ndsidioblastose, /t la multiplicitd des ilots tumoraux, ~ la malignit6.
Dans 12 cas, les sp6cimens r6pondaient au pancr6as distal, dans 2 cas ~ la totalitd du pancrdas. De multiples coupes furent pratiqudes au niveau de chaque pi6ce soumise ~ l'examen. L'impr6gnation l'immunoperoxidase concerna les coupes de 24 tumeurs provenant de 10 patients. Cinq des 10 malades qui pr6sentaient un syndrome de Zollinger-Ellison avaient subi une gastrectomie totale et 3 une intervention pancr6atique pour contrSler leur hypers6cr6tion acide. Les conclusions tirdes de cette 6tude furent les suivantes: tousles malades accusant un syndrome MEN Iet porteurs d'un n6opolasme pancr6atique prdsentaient des 16sions insulaires diffuses rdpondant ~ une n6sidioblastose, ~ une hyperplasie micronodulaire et macronodulaire. Quelques tumeurs produisaient de multiples hormones: gastrine, poly= peptide pancr6atique, glucagon, sdrotonine, V.I.P., somatostatine, test6es par la m6thode. I1 r6sulte de ces constatations que les risques de r6cidive tumorale aprds exdr6se compl6te des tumeurs 6videntes ne sont pas ~t 6carter, encore que l'ex6r6se permette de contrSler longtemps l'endocrinopathie. Ceci est particuli~rement vrai pour les insulinomes hypoglyc6miants. En ce qui concerne les gastrinomes, leur exdr6se peut 6tre suffisante, en particulier lorsque les pr616vements veineux 6tagds montrent qu'ils sont uniques; la gastrectomie concomitante est alors inutile. En revanche, lorsque la gastrine est trouvde en exc6s au niveau de multiples 6chantillons veineux, l'ex6r6se tumorale est insuffisante et la pancrdatectomie totale reprdsente l'intervention indispensable; en fait, son indication est rare.
Resumen
La variedad del espectro de la histopatologfa de las c61ulas insulares en pacientes con sfndrome de neoplasias endocrinas mfiltiples tipo I (NEM I) todavfa no ha sido claramente definido. Atin cuando algunos pacientes poseen tumores discretos que causan sindromes clfnicamente evidentes, otros pueden no exhibir sintomatologfa alguna hasta cuando se hace evidente un carcinoma metastfisico de c61ulas insulares. No se sabe si hay enfermedad difusa de las c61ulas insulares en todo paciente con tumores macrosc6picamente aparentes, ni ademfis se conoce con qu6 frecuencia se desarrollan nuevos tumores en pacientes con sfndrome NEM I despuds de resecci6n local o de pancreatectomfa parcial para tumores primarios de c61ulas insulares. E1 presente estudio intenta definir la extensi6n funcional y anat6mica de la enfermedad de las c61ulas insulares y su relaci6n con la evoluci6n clfnica en pacientes con el sfndrome NEM I.
Los especimenes de resecci6n pancre~itica en 14 pacientes con sfndrome NEM I fueron examinados para hiperplasia, nesidioblastosis, tumores mill-tiples y evidencia de malignidad. Los especfmenes representaron el p~ncreas distal en 12 casos, y la totalidad del p~ncreas en 2. Se tomaron secciones mt~ltiples de cada esp6cimen. La coloraci6n con inmunoperoxidasa fue realizada para gastrina, polip6ptido pancrefitico, glucag6n, serotonina, VIP (p6ptido vasoactivo intestinal), somatostatina y enolasa neuronal especifica en secciones de 24 tumores provenientes de 10 pacientes. Cinco de los 10 pacientes con el sfndrome de Zollinger-Ellison fueron sometidos a gastrectomfa total y otros tres s61o a procedimientos sobre el p~ncreas orientados al control de su hipersecreci6n ficida.
Se llega alas siguientes conclusiones: Todos los pacientes con sindrome NEM I y neoplasias pancre~ticas poseen afecci6n difusa de las c61ulas insulates consistente en nesidioblastosis e hiperplasia micro y macronodular. Algunos tumores producen mt~ltiples hormonas y los pacientes se encuentran en riesgo de desarrollar nuevos tumores, pero la resecci6n de tumores aparentes puede resultar en el control a largo plazo de la endocrinopatfa existente. Esto es particularmente cierto en pacientes con insulinoma e hipoglicemia.
Algunos pacientes con gastrinoma tambi6n pueden ser considerados para resecci6n de su tumor (es) de c61ulas insulates sin gastrectomfa concomitante, especialmente cuando el muestreo venoso transhepfitico demuestra un lugar t~nico de excesiva producci6n de gastrina. Sin embargo, si el muestreo venoso transhep~tico demuestra fuentes difusas de hipergastrinemia, un procedimiento de resecci6n pancre~tica local invariablemente fallar~. La pancreatectomfa total en pacientes con sfndrome NEM I con enfermedad localizada del p~ncreas es el tinico procedimiento quirt~rgico curativo pero est~ rara vez indicado.
